PGENPrecigen, Inc.
Price
+108%1YEnd-of-day closes, not the intraday tick.
Survival is the story here: start there
Quality shaky, hard red flags, the market undecided.
We are a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients. We are leveraging our proprietary technology platforms to develop product candidates designed to target urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. We believe that our array of technology platforms uniquely positions us among other biotechnology companies to advance precision medicine.
In the company’s own words · 10-K filed Mar 25, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Precigen, Inc. (PGEN) reported revenue of $55M in Q2 2026 (quarter ended Jun 30, 2026), up 6323% from the same quarter a year earlier. That came with net income of $20M (37% of revenue). For the full year FY2025, revenue was $9.7M (+147% year on year) and net income −$251M. Its largest product in Q2 2026 was Papzimeos at $53M, 97% of the disclosed total, well ahead of Service at 3.1%. The next results filing is expected around Nov 12, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 4, 2026Precigen Reports Second Quarter 2026 Financial.Earnings release · press release
- May 13, 2026Precigen Reports First Quarter 2026 Financial Results and Business.Earnings release · press release
- Mar 25, 2026Precigen Reports Full Year 2025 Financial Results and Business Updates.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $55.0MThe company’s own SEC segment disclosure.
- Papzimeos$53.1M97%
- Service$1.7M3%
- Exemplar$192.0K0%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.